Fuda Cancer Hospital
Fuda Cancer Hospital
China, Kanton
Rhabdomyosarcoma treatment cost in China typically runs from $85,000 to $142,000 for comprehensive care. Essential procedures like the removal of rhabdomyosarcoma range from $24,500 to $49,500. Total expenses depend on the tumor stage, required therapy cycles, and clinic tier. Patients often find 40% to 60% savings compared to the US. Top cities for this treatment include Guangzhou, Shanghai, and Beijing.
Typical Rhabdomyosarcoma Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients should prioritize clinics specializing in late-stage oncology. Fuda Cancer Hospital offers specialized cryosurgery and NanoKnife technologies for complex cases. For pediatric or adult radiation needs, Dr. Liu Shi Xin at Xiamen Humanity Hospital provides internationally recognized expertise in IMRT. These JCI-accredited facilities offer a high-value alternative for patients needing multidisciplinary care beyond standard chemotherapy protocols.
| China | Türkei | Österreich | |
| Strahlentherapie bei Sarkomen | von $10,500 | von $3,250 | von $18,000 |
| Strahlentherapie bei Darmkrebs | von $11,500 | von $7,000 | von $12,000 |
| Entfernung des Rhabdomyosarkoms | von $24,500 | von $15,000 | von $30,000 |
| Chemotherapie bei Brustkrebs | von $14,800 | von $1,200 | von $15,000 |
| Komplexe Behandlung von Rhabdomyosarkom | von $85,000 | von $45,000 | - |
Bookimed erhebt keine zusätzlichen Gebühren für Rhabdomyosarkom-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Rhabdomyosarkom einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Rhabdomyosarkom-Behandlungsreise nie allein.
Professor Shixin Liu, MD, PhD, ist Fachbereichsleiter des Onkologiezentrums. Zuvor war er Präsident des Krebskrankenhauses der Provinz Jilin und Direktor des Forschungsinstituts für Krebsprävention und -therapie. Er ist Professor der zweiten Ebene und Promotionsbetreuer. Er erhielt die Sonderzulage des Staatsrats, die 4. Auszeichnung 'National Famous Doctor (Outstanding Contribution)' sowie den Ehrentitel 'Vorbild ärztlicher Ethik'.
Er ist auf die umfassende Diagnostik und Behandlung bösartiger Tumoren spezialisiert, mit Schwerpunkt auf präziser Strahlentherapie thorakaler und abdomineller Tumoren. Er beherrscht IMRT, VMAT und SBRT bei Lungen-, Speiseröhren-, Brust- und Rektumkarzinomen.
Zu seinen Leitungsfunktionen zählen die stellvertretenden Vorsitzämter bei CMA Radiation Oncology, CACA Radiotherapy und CACA Particle Therapy. Er gehört dem Ständigen Ausschuss der CSCO an und ist stellvertretender Vorsitzender des CSCO-Expertenkomitees für Strahlenonkologie. Zudem ist er stellvertretender Vorsitzender der CPAM Radiation Oncology und Mitglied des Ständigen Ausschusses der CSMEA. Er ist Vorsitzender der Sektion Strahlenonkologie der Jilin Medical Association. Er gehört den Redaktionsbeiräten des Chinese Journal of Radiation Oncology und des Practical Journal of Cancer an.
Leading Chinese oncology centers follow international protocols by utilizing the CCCG-RMS framework. This structure directly aligns with the US Children Oncology Group and European standards. Multi-disciplinary teams in cities like Guangzhou and Xiamen use standardized risk stratification. These methods match global diagnostic metrics.
Bookimed Expert Insight: A major quality signal in China is the presence of specialized pediatric supervisors. Professor Liu Shi Xin at Xiamen Humanity Hospital holds doctoral supervisor status and national honors. This level of seniority often correlates with high-volume centers that manage complex, rare pediatric sarcomas. Choosing a facility with JCI accreditation ensures rigorous international safety and administrative standards are met.
Patient Consensus: Families emphasize that verifying pathology and staging results is the most critical first step. They note that survival success depends heavily on a hospital's ability to coordinate surgery and radiation in one location.
Standard chemotherapy cycles in China typically follow a 21-day or 28-day schedule. Practitioners prioritize inpatient administration for the first 1 to 3 days of each cycle. This model allows for intensive hydration and clinical monitoring. It adheres to established Chinese Society of Clinical Oncology (CSCO) protocols.
Bookimed Expert Insight: China's oncology infrastructure is built for high-volume standardized care. Fuda Cancer Hospital alone treats over 30,000 international patients. This scale allows clinics to offer over 10 types of minimally invasive therapies. These often serve as alternatives or adjuncts to traditional chemotherapy. Patients should confirm if their protocol includes these specialized interventions early.
Patient Consensus: Parents of pediatric patients note that cycles often depend on blood count recovery. They emphasize that hospital workflows are very fast and standardized. Expect frequent blood labs and bundled supportive care like growth-factor shots during the rest period.
Proton beam therapy is available for rhabdomyosarcoma in China. Major oncology hubs in Shanghai and Guangzhou utilize this precision radiation. These centers effectively treat pediatric and adult soft-tissue sarcomas. Key technologies include active pencil beam scanning and intensity-modulated proton therapy.
Bookimed Expert Insight: While several Chinese centers possess proton technology, expertise in pediatric cases varies significantly. Dr. Liu Shi Xin at Xiamen Humanity Hospital holds leadership roles in national particle therapy committees. Working with a doctor of this caliber ensures the treatment plan aligns with rigorous national standards. Patients should prioritize centers where the radiation lead has extensive experience in both oncology and particle therapy.
Patient Consensus: Families often seek proton therapy specifically to reduce long-term side effects in children. Patients note that finding a high-volume sarcoma team is as vital as the technology itself.
Top hospitals for rhabdomyosarcoma in China include JCI-accredited Fuda Cancer Hospital and Xiamen Humanity Hospital. These centers specialize in multidisciplinary pediatric oncology. They utilize advanced therapies like cryosurgery and precise radiation. Many facilities integrate international protocols to improve outcomes for rare soft tissue sarcomas.
Bookimed Expert Insight: Patient data shows that choosing a hospital with high international volume like Fuda is vital. This clinic has served patients from over 100 countries. Such centers often have more experience with the logistics needed for rare sarcoma cases. They typically offer more flexible, minimally invasive options than standard public hubs.
Patient Consensus: Families emphasize starting treatment with a sarcoma-aware biopsy to avoid surgical complications. Many recommend prioritizing large referral hospitals that host dedicated multidisciplinary tumor boards for rare cancers.
China is a global hub for pediatric oncology trials and novel targeted therapies. The National Medical Products Administration fast-tracks over 60% of oncology agents. Patients access chimeric antigen receptor cell therapies and tyrosine kinase inhibitors. Specialized centers in Guangzhou and Xiamen offer advanced molecular profiling for rare sarcomas.
Bookimed Expert Insight: While trials are numerous, access at centers like Fuda Cancer Hospital depends on specific hospital-run protocols. Our data shows oncology hospitals in China frequently apply over 10 types of minimally invasive therapies. This volume suggests patients should prioritize academic centers with JCI accreditation to ensure rigorous clinical trial standards.
Patient Consensus: Patients emphasize that molecular profiling is a necessary first step before pursuing targeted therapy. Many note that language barriers and record translations are significant hurdles when accessing experimental protocols.
Chinese sarcoma centers provide advanced localized therapies including High-Intensity Focused Ultrasound, cryosurgery, and NanoKnife. These minimally invasive techniques target tumors while preserving healthy tissue and organ function. JCI-accredited facilities like Fuda Cancer Hospital combine these procedures with precision radiotherapy to manage complex or recurrent rhabdomyosarcoma cases effectively.
Bookimed Expert Insight: Patient data from Fuda Cancer Hospital highlights a significant trend toward multi-modality local control. Clinics often employ over 10 types of minimally invasive therapies. This approach is specifically used for late-stage cancers to avoid intensive chemotherapy. Choosing centers with high patient volumes, like those serving over 30,000 international patients, ensures access to these concentrated technologies under one roof.
Patient Consensus: Patients note that Chinese centers often prioritize limb-sparing reconstructions over amputation for large tumors. Many families appreciate the willingness to perform repeat local treatments for recurrences rather than switching solely to systemic palliative care.